Bay Street News, June 22nd, 2020

Update Provided Phase I Study of MT-5111 in HER2-positive CancersConference Call and Webcast to Discuss AACR Posters on June 25th […]

TROY, Mich., June 22, 2020 (GLOBE NEWSWIRE) — Kelly, a global leader in providing workforce solutions, today announced the appointment […]

Peptide-drug conjugates TH1902 and TH1904 show significant reduction in the formation of vasculogenic mimicry by targeting the sortilin receptorCurcumin shows […]

RICHMOND HILL, Ontario, June 22, 2020 (GLOBE NEWSWIRE) — Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology […]

Interim data demonstrate that HB‑101 is well toleratedHB-101 elicits T cell and B cell responses in the target populationNEW YORK […]

SAN JOSE, Calif., June 22, 2020 (GLOBE NEWSWIRE) — Zscaler, Inc. (Nasdaq: ZS) today announced that it intends to offer $1.0 […]

– AUTO5 in T cell lymphoma – new in vitro and in vivo data presented demonstrating highly selective targeting of […]

DURHAM, N.C., June 22, 2020 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to […]

GAITHERSBURG, Md., June 22, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the […]

MALVERN, Pa., June 22, 2020 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company […]